Can RFK Jr. Fix Our Dysfunctional Public Health Agencies?
His priorities may not be the drastic reforms that are actually needed.
His priorities may not be the drastic reforms that are actually needed.
Many seriously ill people die waiting for the FDA to approve drugs that regulators in other advanced countries have already approved.
Apparently consumers are too stupid to know that butter contains milk.
Not only are microplastics essentially unavoidable, but the alleged harm they pose has been wildly overblown.
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical company.
The FDA’s latest nutrition rules target dried cherries and cranberries, putting small farmers at risk while offering zero benefits to consumers.
An FDA advisory committee concluded that MDMA's benefits had not been shown to outweigh its risks.
The host of Why We Can't Have Nice Things returns to discuss the podcast's second season, which focuses on how government makes Americans poorer and sicker.
Government pre-approval for every label could crush craft breweries. And do you really want to force the Carthusian monks who make Green Chartreuse to reveal their ingredients?
The FDA, which approved the protocols for the studies it now questions, is asking for an additional Phase 3 clinical trial, which would take years and millions of dollars.
Wandercraft, the French company that developed the exoskeleton suit, recently got FDA approval to use them for stroke rehab in the U.S.
The 5th Circuit ruled that the agency violated the Administrative Procedure Act when it rejected applications from manufacturers of flavored nicotine e-liquids.
The majority and the dissenters agree that the drug was "central" to "the opioid crisis," even though there is little evidence to support that thesis.
The agency's inscrutable approach to harm-reducing nicotine products sacrifices consumer choice and public health on the altar of youth protection.
As the DEA relentlessly tightens regulations on pain meds, the FDA refuses to approve a safer alternative already being used in similar countries.
Not a single justice was impressed by the unimpressive standing theories offered in Alliance for Hippocratic Medicine v. FDA.
Policies that increase the use of traditional cigarettes are unlikely to improve public health.
Plus: Hezbollah escalates, congestion pricing halted, the Didion-Dunne family feud, GIMBYism, and more...
The panel's recommendation, based on several concerns about two clinical trials, is a serious setback for a promising PTSD treatment.
Lab-grown meat bans don't protect consumers, but they do protect ranchers and farmers from competition.
Moving marijuana to Schedule III, as the DEA plans to do, leaves federal pot prohibition essentially untouched.
The change from Schedule I to Schedule III is welcome, but removing it from the schedules altogether is the best option.
New red tape will result in fewer safe and effective diagnostic tests.
One hundred Nobel laureates agree: The campaign against biotech-enhanced golden rice is a "crime against humanity."
The research the FDA relies upon to claim banning menthol cigarettes would improve public health is not aligned with the agency's approach to tobacco regulation.
The government still blames the private sector despite its own role in creating, exacerbating, and prolonging the shortage.
After botching COVID test approvals, the Food and Drug Administration wants power over thousands of other tests.
Live commentary on the Supreme Court oral argument in FDA v. Alliance for Hippocratic Medicine
Plus: Abortion pill case, another fatal subway crime, China's Cultural Revolution, and more...
The threshold issue in today's oral argument is Article III standing, and that issue should be determinative.
The Department of Justice is asking the Supreme Court to review the Fifth Circuit's Rejection of the FDA's "Surprise Switcheroo."
The market offers many alternatives to bad desserts. We don’t need the FDA to step in.
In the name of safety, politicians did many things that diminished our lives—without making us safer.
"Following the science" as the Supreme Court considers the safety and efficacy of medical abortions.
The DEA is cracking down on manufacturers, hurting patients who genuinely need those drugs.
The Court also rejects a late-filed amicus briefs from the American Bar Association, but accepts one from former FDA Commissioners.
The president criticized companies for selling "smaller-than-usual products" whose "price stays the same." But it was his and his predecessor's spending policies that caused the underlying issue.
In 2024, the FDA will decide whether or not MDMA can be used to treat patients suffering from PTSD.
Zyn pouches are a dramatically safer alternative to smoking.
The points about marijuana's risks and benefits that the department now concedes were clear long before last August.
Heated tobacco products are coming to America, at long last. How will they change the landscape for smokers and prohibitionists?
Another significant court loss for the Food & Drug Administration's arbitrary approach to regulating vaping products.
The Court announced today that it would take up a case involving access to the abortion-inducing drug mifepristone.
The Court granted two petitions for certiorari seeking review of a controversial lower court decision limiting federal approval of mifepristone.
Your donations help us take on today's Prohibitionists.
Lots of Americans have an intolerance to FODMAPs—the sugars prevalent in garlic, onion, and many other foods.
"The FDA's regulations related to animal testing no longer fully conform with applicable law," writes the Kentucky senator.
Policies inspired by that exaggerated threat continue to undermine the harm-reducing potential of e-cigarettes.